Effects of coenzyme Q10 (CoQ10) supplementation on semen quality and seminal oxidative stress of idiopathic oligoasthenoteratozoospermic (iOAT) infertile men

Effects of three-month supplementation with 200 mg of ubiquinone (coenzyme Q10 [CoQ10]) on semen quality, antioxidant enzymes of seminal plasma, sperm DNA fragmentation, total antioxidant capacity and isoprostane of seminal plasma in idiopathic oligoasthenoteratozoospermic infertile men: a double-blind randomised placebo-controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN29954277

Enrollment

Registered

2008-12-03

Start date

2008-10-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male infertility Urological and Genital Diseases Male infertility

Interventions

The participants will be randomly allocated to the following two arms (randomisation ratio 1:1): Intervention group: 100 mg ubiquinone capsule (oral) (Pharmed Int. Inc., Canada) twice daily with lun

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Men 20-45 years 2. With idiopathic oligoasthenoteratozoospermia (sperm count 5-20 x 10^6/mL ,sperm motility according to World Health Organization (WHO) 1999 criteria <50% and normal sperm morphology <30%) 3. Seminal white blood cells <1 x 10^6/mL 4. At least 1 year of infertility 5. Normal serum levels of gonadotropines, testosterone and prolactine 6. Absence of systemic diseases, treatment with drug or supplement use in the 3 months before enrolment 7. Absence of infectious genital disease and anatomical abnormalities of the genital tract 8. Absence of smoking, drug addiction or alcohol consumption 9. Absence of occupational chemical exposure 10. Absence of surgical history on testis or vasodeferane

Exclusion criteria

Exclusion criteria: Discontinuation in supplement usage.

Design outcomes

Primary

Measure	Time frame
1. Super oxide dismutase and glutathione peroxidase activity of seminal plasma and 15-F2 alpha isoprostane concentration will be measured by commercial kits 2. Catalase activity of seminal plasma 3. Total antioxidant capacity of seminal plasma 4. Concentration of ubiquionone in seminal plasma will be measured by High Performance Liquid Chromatography (HPLC) at baseline and 3 months 5. Dietary intake will be assessed by 3 days dietary recall at baseline, 45 days and 3 months and will be analysed by nutrition analysis software (Food Processor II) All primary outcomes will be assessed at baseline and 3 months	—

Measure

Time frame

1. Super oxide dismutase and glutathione peroxidase activity of seminal plasma and 15-F2 alpha isoprostane concentration will be measured by commercial kits 2. Catalase activity of seminal plasma 3. Total antioxidant capacity of seminal plasma 4. Concentration of ubiquionone in seminal plasma will be measured by High Performance Liquid Chromatography (HPLC) at baseline and 3 months 5. Dietary intake will be assessed by 3 days dietary recall at baseline, 45 days and 3 months and will be analysed by nutrition analysis software (Food Processor II) All primary outcomes will be assessed at baseline and 3 months

—

Secondary

Measure	Time frame
1. Sperm morphology and motility will be assessed with spermiogeram in accordance with the WHO 1999 criteria and also by computer-assisted sperm analysis 2. Sperm DNA fragmentation will be measured by Sperm Chromatin Structure Analysis (SCSA) All secondary outcomes will be assessed at baseline and 3 months	—

Countries

Iran

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026